Company: CORT
Filing Date: 2025-05-05
Form Type: 10-Q
Source: 0001628280-25-022173
Chunk: 32

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-05-05
Form: 10-Q
Item: Part I, Item 8
Chunk 32
---
repaid expenses and other current assetsMarch 31,2025December 31,2024 (in thousands)Prepaid expenses$8,554 $9,492 Deferred clinical materials4,316 4,493 Clinical deposits1,817 1,817 Other current assets24,866 6,078 Total prepaid expenses and other current assets$39,553 $21,880 As of March 31, 2025, other current assets included $18.2 million of non-trade receivables relating to proceeds from stock option exercises.Accrued and other liabilitiesMarch 31,2025December 31,2024 (in thousands)Government rebates$44,232 $41,580 Accrued compensation36,420 41,731 Accrued selling and marketing costs4,197 3,345 Other4,026 4,044 Total accrued and other liabilities$88,875 $90,700 Other assetsAs of each of March 31, 2025 and December 31, 2024, other assets included $5.6 million of deposits for clinical trials.

9

3. Available-for-Sale Marketable Securities and Fair Value Measurements

The available-for-sale securities in our condensed consolidated balance sheets are as follows:March 31,2025December 31,2024(in thousands)Cash equivalents$69,663 $98,436 Short-term marketable securities232,944 255,669 Long-term marketable securities248,041 219,831 Total marketable securities$550,648 $573,936 The following table presents our available-for-sale securities grouped by asset type: Fair ValueHierarchyLevelMarch 31, 2025December 31, 2024Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair ValueAmortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value  (in thousands)Corporate bondsLevel 2$382,898 $593 $(217)$383,274 $373,440 $333 $(529)$373,244 Commercial paperLevel 24,886 2 — 4,888 9,771 6 (2)9,775 U.S. government agency securitiesLevel 232,993 — (25)32,968 7,999 — (2)7,997 U